Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Coronary Artery Disease
Interventions: Clopidogrel, Placebo; Drug
Lead sponsor: Deutsches Herzzentrum Muenchen; Other
Eligibility: 18 Years and older
Enrollment: 4,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions: MGL-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Orlando, Florida • Saint Paul, Minnesota • San Antonio, Texas

Conditions: Skin Laxity (Submental and Neck), Facial Skin Laxity, Submental Tissue Laxity
Interventions: ULTRAFORMER MPT PLUS, Ulthera System; Device
Lead sponsor: CLASSYS Inc.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 273 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Los Angeles, California • Charlotte, North Carolina • Wilmington, North Carolina + 2 more

Conditions: HIV Infections
Interventions: Hydroxyurea, Efavirenz, Stavudine, Didanosine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Adults
Interventions: methylnaltrexone, placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Labor Induction, Cervical Ripening
Interventions: dinoprostone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 3
States / cities: Brooklyn, New York • Flushing, New York • New York, New York

Conditions: Crohn's Disease
Interventions: Matching Placebo for Upadacitinib, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 119
States / cities: Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more

Conditions: Obesity, Over-weight, Hypothalamic Injury, Craniopharyngioma
Interventions: ZGN-440 sterile diluent, ZGN-440 for injectable suspension; Drug
Lead sponsor: Zafgen, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Saint Paul, Minnesota • Nashville, Tennessee

Conditions: Healthy Volunteer
Interventions: TRL1068, a human monoclonal antibody; Drug
Lead sponsor: Trellis Bioscience LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Participants
Interventions: BMS-986256, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Anaheim, California • Lenexa, Kansas

Conditions: Severe Sepsis, Septic Shock
Interventions: BMS-936559, Placebo; Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 13
States / cities: Sacramento, California • Denver, Colorado • Gainesville, Florida + 10 more

Conditions: Psoriasis
Interventions: XP23829 400 mg QD, XP 23829 800 mg QD, XP23829 400 mg BID, Placebo; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 25 more

Conditions: Covid19
Interventions: Angiotensin-(1-7), Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: Pomalidomide, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Atopic Dermatitis Eczema
Interventions: Roflumilast Cream, Vehicle cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 44
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Inglewood, California + 38 more

Conditions: Healthy
Interventions: BIIB061, Placebo; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Asthma
Interventions: Placebo, BI 54903, Fluticasone propionate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 41
States / cities: Fountain Valley, California • Fullerton, California • Huntington Beach, California + 38 more

Conditions: Celiac Disease
Interventions: larazotide acetate; Drug
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Myasthenia Gravis
Interventions: IGIV-C, Placebo; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Orange, California • New Haven, Connecticut • Jacksonville, Florida + 11 more

Conditions: Pediatric Obesity, Obesity
Interventions: Healthy Caregivers- Healthy Children Toolkit, Safety Curriculum; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 2 Years to 5 Years
Enrollment: 2,289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 2 Diabetes
Interventions: CAT 1004, Placebo; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Osteomyelitis, Diabetic Foot Osteomyelitis
Interventions: Bacteriophage Therapy, Placebo; Biological · Other
Lead sponsor: Adaptive Phage Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Tuscon, Arizona • Fairfield, California • Torrance, California + 11 more

Conditions: Psoriasis, Atopic Dermatitis
Interventions: XmAb27564, Placebo; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Sherman Oaks, California • Thousand Oaks, California • Coral Gables, Florida + 3 more

Conditions: Lupus Nephritis
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 17
States / cities: Glendale, Arizona • Phoenix, Arizona • La Jolla, California + 13 more

Search by objective public record fields.

Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue

A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

Combined Agent Randomized Trial of Induction of Labor

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers

An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants

Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

Safety Study of Larazotide Acetate to Treat Celiac Disease.

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Healthy Caregivers-Healthy Children (HC2) Phase II

A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes

Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis